Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | NQO2 | P16083 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | RBP4 | P02753 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30307699 | 0.87 | KDM4E (0.45) | ALDH1A1KDM4EMAPTPKMNQO2 | |
| SCHEMBL112719 | 0.87 | KDM4E (0.45) | ALDH1A1KDM4EMAPTPKMNQO2 | |
| SCHEMBL16506338 | 0.82 | CYP1A2 (0.51) | ALDH1A1KDM4EMAPTMAPK1SMN1; SMN2 | |
| SCHEMBL24046189 | 0.81 | NQO2 (0.43) | ALDH1A1KDM4EMAPTPKMNQO2 | |
| SCHEMBL10198533 | 0.81 | LMNA (0.47) | ALDH1A1KDM4ENQO2LMNAMAPK1 | |
| SCHEMBL2706709 | 0.81 | LMNA (0.47) | ALDH1A1KDM4ENQO2LMNAMAPK1 | |
| SCHEMBL16232808 | 0.81 | KMT2A (0.46) | ALDH1A1KDM4EMAPTPKMNQO2 | |
| SCHEMBL4826028 | 0.81 | KDM4E (0.50) | ALDH1A1KDM4EMAPTPKMLMNA | |
| SCHEMBL1760242 | 0.80 | ALDH1A1 (0.55) | ALDH1A1KDM4ENQO2LMNAMAPK1 | |
| SCHEMBL1222948 | 0.80 | NQO2 (0.49) | ALDH1A1KDM4EMAPTPKMNQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 384 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117062813-B | Polycyclic compound and application thereof | 四川汇宇制药股份有限公司 | 2026-05-19 | — | — | CN | disclosed |
| US-20260085048-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | EPIVARIO INC (US) | 2026-03-26 | — | — | US | disclosed |
| US-20260028365-A1 | TYROSINE KINASE 2 INHIBITORS AND USES THEREOF | BIOGEN MA INC (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4685141-A1 | ISOINDOLINE DERIVATIVE, BENZOINDOLE DERIVATIVE AND USE THEREOF | Shanghai Helioson Pharmaceutical Co., Ltd. (CN) | 2026-01-28 | — | — | EP | disclosed |
| US-12509451-B2 | Heteroaryl amide inhibitors of CD38 | NAPA THERAPEUTICS LIMITED (IM) | 2025-12-30 | — | — | US | disclosed |
| US-20250326739-A1 | CD38 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4635949-A1 | SUBSTITUTED TETRAHYDROCYCLOPENTYL[C]PYRROLE DERIVATIVE, PREPARATION METHOD, INTERMEDIATE AND USE THEREOF | Jiangsu NHWA Pharmaceutical Co., Ltd (CN) | 2025-10-22 | — | — | EP | disclosed |
| EP-4630406-A1 | AMIDE COMPOUNDS AS ACTIVATORS OF THE POTASSIUM CHANNELS KV7.2/KV7.3 USEFUL IN THE TREATMENT OF CNS AND PNS DISORDERS | ANGELINI PHARMA S.P.A. (IT) | 2025-10-15 | — | — | EP | disclosed |
| US-12441689-B2 | ACSS2 inhibitors and methods of use thereof | EPIVARIO, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250304577-A1 | TYK2 INHIBITORS | BIOGEN MA INC. | 2025-10-02 | — | — | US | disclosed |
| US-6440973-B1 | Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents | AMGEN INC. | 2002-08-27 | — | — | US | disclosed |
| US-6342503-B1 | ANTIDEPRESSANTS, EATING DISORDERS | DUPONT PHARMACEUTICALS COMPANY | 2002-01-29 | — | — | US | disclosed |
| US-6180643-B1 | ANTAGONIST OF INTERLEUKINS, TUMOR NECROSIS FACTOR | AMGEN INC. | 2001-01-30 | — | — | US | disclosed |
| US-6107301-A | PSYCHOLOGICAL DISORDERS | DUPONT PHARMACEUTICALS COMPANY (US) | 2000-08-22 | — | — | US | disclosed |
| CN-1246856-A | Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents | AMGEN INC (US) | 2000-03-08 | — | — | CN | disclosed |
| WO-1998022457-A9 | ARYL AND HETEROARYL SUBSTITUTED FUSED PYRROLE ANTIINFLAMMATORY AGENTS | — | 1998-08-20 | — | — | WO | disclosed |
| CN-1142817-A | 1N-alkyl-N-arylpyrimidinamines and derivatives thereof | DU PONT MERCK PHARMA (US) | 1997-02-12 | — | — | CN | disclosed |
| EP-0723533-A1 | 1N-ALKYL-N-ARYLPYRIMIDINAMINES AND DERIVATIVES THEREOF | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-07-31 | — | — | EP | disclosed |
| WO-1995010506-A1 | 1N-ALKYL-N-ARYLPYRIMIDINAMINES AND DERIVATIVES THEREOF | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-04-20 | — | — | WO | disclosed |
| US-5324710-A | Sulfonated heterocyclic carboxamides and their use as herbicides, and growth regulators | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304577-A1 | TYK2 INHIBITORS | TYK2, JAK2, JAK1 | ALDH1A1 4708/4885KDM4E 549/4885MAPT 1334/4885 |
| US-20250326739-A1 | CD38 MODULATORS AND USES THEREOF | CD38, CD22, CD47 | ALDH1A1 141/4885KDM4E 3816/4885MAPT 3109/4885 |
| US-12509451-B2 | Heteroaryl amide inhibitors of CD38 | CD38, FCGRT, BCL6 | ALDH1A1 215/4885KDM4E 2756/4885MAPT 4147/4885 |
| US-20260085048-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | ACSS2, GLS2, ACSL3 | ALDH1A1 1031/4885KDM4E 1262/4885MAPT 3989/4885 |
| US-12441689-B2 | ACSS2 inhibitors and methods of use thereof | ACSS2, ADSS2, GLS2 | ALDH1A1 347/4885KDM4E 1691/4885MAPT 2640/4885 |
| US-20260028365-A1 | TYROSINE KINASE 2 INHIBITORS AND USES THEREOF | TYK2, ERBB2, ROS1 | ALDH1A1 2989/4885KDM4E 1141/4885MAPT 4351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.